<DOC>
	<DOC>NCT01933152</DOC>
	<brief_summary>Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and December 31, 2009 must be consecutively screened and, if eligible, enrolled. Patients will be followed up at maximum until December 31, 2011. Switch to any other Anti vascular endothelial growth factor (anti VEGF) treatment will be documented. For each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.</brief_summary>
	<brief_title>Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Diagnosis of wet Agerelated Macular Degeneration Start of antiVEGF therapy with ranibizumab (Lucentis) between January 1, 2009 and December 31, 2009 Informed consent form signed Participation in an investigational study during antiVEGF therapy (from start up to December 31, 2011) that involved treatment with any drug or device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>wAMD</keyword>
	<keyword>anti-VEGF</keyword>
</DOC>